Moderate Evidence
Research Overview
Melanotan-1 Research for Erythropoietic Protoporphyria (EPP)
An overview of research and source records on Melanotan-1 in the context of erythropoietic protoporphyria (epp).
Research Summary
One pivotal publication reports two randomized placebo-controlled implant trials, enrolling 94 US and 74 European EPP participants. Pain-free direct-sunlight time improved in both trials. German and Austrian follow-up cohorts add observational context but have no untreated randomized comparison. US and EU approvals concern the regulated Scenesse implant in adults with EPP.
References
Open a reference to inspect its source record. A citation does not establish a clinical benefit.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.